PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced key appointments across its leadership team. These include:
Related news for (PMVP)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/10/25 07:00 AM
- PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
- 24/7 Market News Snapshot 10 September, 2025 – PMV Pharmaceuticals, Inc (NASDAQ:PMVP)
- PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
- PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights